NCT04810091View on ClinicalTrials.gov

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

May 18, 2021

Primary Completion Date

October 26, 2025

Study Completion Date

October 26, 2025

Conditions
Locally Advanced Neuroendocrine NeoplasmMetastatic Neuroendocrine Neoplasm
Interventions
DRUG

Placebo Administration

Given PO

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Telotristat Ethyl

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT04810091 - Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor | Biotech Hunter | Biotech Hunter